RxDoctor Payments Data

Kimberly Montgomery

Family · Charlotte, NCNPI 1013979228

Payments from drug & device makers

$792in general payments, 2019–2025

Across 51 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$244
  • Novo Nordisk$108
  • Lilly USA, LLC$80
  • Amgen$74
  • Exact Sciences$63
  • Bayer$40
  • plus $182 from 8 others

What the payments were for

  • Food & beverage$72792%
  • Education$658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie22$244
Novo Nordisk7$108
Lilly USA, LLC3$80
Amgen5$74
Exact Sciences3$63
Bayer2$40
Pfizer2$33
Abbott1$25
Otsuka America Pharmaceutical, Inc.1$23
Mindray DS USA, Inc.1$22
Nevro Corp.1$21
GSK1$20
Boehringer Ingelheim1$20
Gilead1$19

How this compares

$792 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$23,079
Medicare patients
87
Services billed
678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$121,718
OzempicSemaglutide38$77,349
LinzessLinaclotide40$37,210
EliquisApixaban38$31,679
JardianceEmpagliflozin21$28,222
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$19,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,966
FarxigaDapagliflozin Propanediol21$17,021
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$5,078
Wixela InhubFluticasone Propion/Salmeterol16$2,628
Risedronate Sodium18$2,592
Albuterol Sulfate HfaAlbuterol Sulfate68$2,222
Gabapentin126$1,952
Duloxetine Hcl64$1,693
Rosuvastatin Calcium144$1,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$80$121,71878 claims
Novo NordiskOzempic$108$77,34938 claims
AbbVieLinzess$244$37,21040 claims
PfizerEliquis$33$31,67938 claims
Boehringer IngelheimJardiance$20$28,22221 claims
GSKTrelegy Ellipta$20$17,96620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.

Other family in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →